Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Beneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension

  • Oh, Il-Young (Department of Internal Medicine, Seoul National University College of Medicine, Bundang Hospital) ;
  • Seo, Myung-Ki (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Hae-Young (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Kim, Soon-Gil (Department of Internal Medicine, Hanyang University College of Medicine, Guri Hospital) ;
  • Kim, Ki-Sik (Department of Internal Medicine, Daegu Catholic University College of Medicine) ;
  • Kim, Won-Ho (Department of Internal Medicine, Chonbuk National University College of Medicine) ;
  • Hyon, Min-Soo (Department of Internal Medicine, Soonchunhyang University College of Medicine) ;
  • Han, Kyoo-Rok (Department of Internal Medicine, Hallym University College of Medicine) ;
  • Lim, Se-Joong (Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital) ;
  • Kim, Cheol-Ho (Department of Internal Medicine, Seoul National University College of Medicine, Bundang Hospital)
  • Received : 2010.03.03
  • Accepted : 2010.04.09
  • Published : 2010.10.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Efonidipine hydrochloride, an L- and T-type dual calcium channel blocker, is suggested to have a heart rate (HR)-slowing action in addition to a blood pressure (BP)-lowering effect. The aim of this study was to determine the effect of efonidipine on HR and BP in patients with mild-to-moderate hypertension. Subjects and Methods: In a multi-center, prospective, open-labeled, single-armed study, we enrolled 53 patients who had mild-to-moderate hypertension {sitting diastolic BP (SiDBP) 90-110 mmHg}. After a 2-week washout, eligible patients were treated with efonidipine (40 mg once daily for 12 weeks). The primary end point was the change in HR from baseline to week 12. The secondary endpoint included the change in trough sitting BP and 24-hour mean BP between baseline and week 12. Laboratory and clinical adverse events were monitored at each study visit (4, 8, and 12 weeks). Results: Fifty-two patients were included in the inten-tion-to-treat analysis. After 12 weeks of treatment with efonidipine, the resting HR decreased significantly from baseline to week 12 {from 81.5${\pm}$5.3 to 71.8${\pm}$9.9 beats/minute (difference, -9.9${\pm}$9.0 beats/minute), p<0.0001}. The trough BP {sitting systolic blood pressure (SiSBP) and SiDBP} and 24-hour mean BP also decreased significantly (SiSBP: from 144.6${\pm}$8.2 to 132.9${\pm}$13.5 mmHg, p<0.0001; SiDBP: from 96.9${\pm}$5.4 to 88.3${\pm}$8.6 mmHg, p<0.0001, 24-hour mean systolic BP: from 140.4${\pm}$13.5 to 133.8${\pm}$11.6 mmHg, p<0.0001; 24-hour mean diastolic BP: from 91.7${\pm}$8.7 to 87.5${\pm}$9.5 mmHg, p<0.0001). Con-clusion: Efonidipine was effective in controlling both HR and BP in patients with mild-to-moderate hypertension.

Keywords

References

  1. Tanaka H, Shigenobu K. Efonidipine hydrochloride: a dual blocker of L- and T-type ca(2+) channels. Cardiovasc Drug Rev 2002;20:81-92.
  2. Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988;395:233-53. https://doi.org/10.1113/jphysiol.1988.sp016916
  3. Masumiya H, Shijuku T, Tanaka H, Shigenobu K. Inhibition of myocardial L- and T-type Ca2+ currents by efonidipine: possible mechanism for its chronotropic effect. Eur J Pharmacol 1998;349:351-7. https://doi.org/10.1016/S0014-2999(98)00204-0
  4. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 2007;30:691-7. https://doi.org/10.1291/hypres.30.691
  5. Shimizu M, Ogawa K, Sasaki H, et al. Effects of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, openlabel pilot study. Current Ther Res 2003;64:707-14. https://doi.org/10.1016/j.curtheres.2003.11.004
  6. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74. https://doi.org/10.1093/eurheartj/ehi190
  7. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951-8. https://doi.org/10.1056/NEJMoa043012
  8. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006;24:603-10. https://doi.org/10.1097/01.hjh.0000217838.49842.1e
  9. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-54. https://doi.org/10.1016/0002-8703(93)90128-V
  10. Chung JW, Lee HY, Kim CH, et al. Losartan/hydrochlorothiazide fixed combination versus amlodipine monotherapy in Korean patients with mild to moderate hypertension. Korean Circ J 2009;39:151-6. https://doi.org/10.4070/kcj.2009.39.4.151
  11. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-30. https://doi.org/10.1016/j.jacc.2007.04.079
  12. Cha DH, Cha YS, Kook JH, et al. Clinical efficacy of carvedilol in patients with moderate to severe congestive heart failure. Korean Circ J 1998;28:523-31.
  13. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT): a randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.
  14. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-53. https://doi.org/10.1001/archinte.153.3.345
  15. Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31. https://doi.org/10.1161/01.CIR.92.5.1326
  16. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5. https://doi.org/10.1001/jama.274.8.620
  17. Kim DW, Seo JD, Cho SW, et al. Antihypertensive efficacy and safety of perindopril versus nifedipine in high salt intake essential hypertensives: a double-blind parallel group study. Korean Circ J 1994;24:156-63. https://doi.org/10.4070/kcj.1994.24.1.156
  18. Furukawa T, Nukada T, Miura R, et al. Differential blocking action of dihydropyridine Ca2+ antagonists on a T-type Ca2+ channel (alpha1G) expressed in Xenopus oocytes. J Cardiovasc Pharmacol 2005;45:241-6. https://doi.org/10.1097/01.fjc.0000154374.88283.15
  19. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther 1999;291:464-73.
  20. Morimoto S, Jo F, Maki K, Iwasaka T. Effects of efonidipine hydrochloride on heart rate and circulatory changes due to stress. Clin Exp Hypertens 2009;31:83-91. https://doi.org/10.1080/10641960802627363
  21. Kinoshita H, Kuwahara K, Takano M, et al. T-type Ca2+ channel blockade prevents sudden death in mice with heart failure. Circulation 2009;120:743-52. https://doi.org/10.1161/CIRCULATIONAHA.109.857011
  22. Bloch MJ. British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far? J Clin Hypertens 2007;9:99-102. https://doi.org/10.1111/j.1524-6175.2007.06312.x
  23. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension: a meta-analysis. Lancet 2005;366:1545-53. https://doi.org/10.1016/S0140-6736(05)67573-3
  24. Palatini P, Benetos A, Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 2006;66:133-44. https://doi.org/10.2165/00003495-200666020-00001

Cited by

  1. Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension vol.29, pp.4, 2010, https://doi.org/10.1038/jhh.2014.79
  2. Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine vol.53, pp.4, 2010, https://doi.org/10.1165/rcmb.2015-0009oc
  3. Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects vol.39, pp.1, 2019, https://doi.org/10.1007/s40261-018-0722-5